MedTrace Logo

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

NCT00006187 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2009-12-11

No results posted yet for this study

Summary

This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month randomized withdrawal period. For this phase approximately 10% of the patients will remain on the active drug.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Investigational drug

Sponsors & Collaborators

Principal Investigators

  • Klaus Beck, MD, PhD · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006187 on ClinicalTrials.gov